Patients must have biopsy-proven newly diagnosed polymorphic or monomorphic PTLD using the World Health Organization (WHO) classification and that is:\r\n* CD20 positive\r\n* EBV positive by Epstein-Barr virus early ribonucleic acid (RNA) (EBER) in situ hybridization (preferred) and/or LMP immunoperoxidase stainingXx_NEWLINE_xXHistologic diagnosis of CD30-positive classical HL as defined by the 2008 World Health Organization (WHO) Classification of Hematological diseases; nodular lymphocyte predominant Hodgkin lymphoma is not eligibleXx_NEWLINE_xXPatients must have newly diagnosed B lymphoblastic leukemia (2008 World Health Organization [WHO] classification) (also termed B-precursor acute lymphoblastic leukemia); patients with Down syndrome are also eligibleXx_NEWLINE_xXHistological evidence of World Health Organization (WHO) grade III anaplastic glioma or WHO grade II low grade glioma with locally diagnosed combined 1p/19q loss and the presence of an either IDH1 or IDH2, both as established by a local or referenced laboratory qualified for the study\r\n* Note: mixed gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic predominance, as long as the tumor is also co-deleted for 1p and 19qXx_NEWLINE_xXHistologically proven diagnosis of glioblastoma (World Health Organization [WHO] grade IV) confirmed by central review prior to step 2 registrationXx_NEWLINE_xXPatients must have high-grade bladder cancer as defined by 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classificationXx_NEWLINE_xXNewly diagnosed patients with CD-22 positive B-cell acute lymphoblastic leukemia (World Health Organization [WHO] criteria) are eligible; patients with Burkitt type ALL are NOT eligibleXx_NEWLINE_xXPatients with low grade glioma patients (World Health Organization [WHO] grades I and II) are not eligibleXx_NEWLINE_xXNeuroendocrine tumors (NETs), grade 2 and grade 3 according to World Health Organization classification.Xx_NEWLINE_xXDocumented diagnosis of MDS according to World Health Organization (WHO) criteria that meets International Prognostic Scoring System (IPSS) classification of low or intermediate-1 risk disease at screening as determined by microscopic and standard cytogenetic analyses of the bone marrow and peripheral complete blood count (CBC) and who are refractory to or are not amenable or eligible for approved MDS therapy. The second expansion cohort will enroll patients with low or intermediate-1 risk MDS with symptomatic anemia, who, experienced ESA treatment failure or do not qualify (serum erythropoietin level > 500 U) for ESA treatment and who have not received prior HMA and/or lenalidomide.Xx_NEWLINE_xXConfirmed diagnosis of primary or secondary AML [any subtype except acute promyelocytic leukemia (APL)] according to World Health Organization (WHO) classification or MDS with an International Prognostic Scoring System (IPSS) risk category of Intermediate 2 or High RiskXx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient must not have Burkitt’s lymphoma/leukemia based on the World Health Organization (WHO) criteriaXx_NEWLINE_xXPatients with recurrent diffuse intrinsic pontine glioma (DIPG) with typical radiographic appearance who have undergone biopsy are eligible provided there is histologic confirmation of malignant glioma World Health Organization (WHO) II-IV; Rb1 screening for these patients is required only if adequate tissue is availableXx_NEWLINE_xXDose Escalation - Relapsed or refractory AML (excluding acute promyelocytic leukemia) or PDCN, based on World Health Organization Classification. All patients enrolled on this study will have CD123+ disease.Xx_NEWLINE_xXDiagnosis of one of the following histologic subtypes of PTCL, pathologically-confirmed, as defined by the World Health Organization:Xx_NEWLINE_xXDiagnosis of AML per World Health Organization (WHO) criteria (except acute promyelocytic leukemia)Xx_NEWLINE_xXMorphologically confirmed diagnosis of MDS or MDS/MPN in accordance with World Health Organization (WHO) diagnostic criteriaXx_NEWLINE_xXHistologically confirmed diagnosis of classical Hodgkin lymphoma (excluding nodular lymphocyte predominant Hodgkin lymphoma) according to the World Health Organization (WHO) classification, with hematopathology review at the participating institutionXx_NEWLINE_xXSubject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) which is relapsed or refractory after failing at least 1 regimen and is not a candidate for established salvage treatment regimensXx_NEWLINE_xXDocumented pathological evidence of MDS as defined by the World Health Organization (WHO) criteriaXx_NEWLINE_xXHave histologically confirmed World Health Organization (WHO) grade II or III meningioma that is progressive or recurrent; metastatic meningiomas are allowed; participants must have failed maximal safe resection and radiation therapyXx_NEWLINE_xXSingle agent (SA) Dose Escalation: Histologically or cytologically proven acute leukemia or high-risk MDS as defined by the World Health Organization (WHO) criteria and IPSS-R, respectively, that is relapsed or refractory (R/R) to standard therapy or for whom standard treatments are contraindicated, ORXx_NEWLINE_xXWorld Health Organization (WHO) performance status =< 2Xx_NEWLINE_xXDiagnosis of PTCL according to the most recent edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues, as follows:Xx_NEWLINE_xXRefractory or relapsed lymphoma (per World Health Organization (WHO) Classification system)Xx_NEWLINE_xXDiagnosis of MDS (de novo or secondary) by bone marrow biopsy based on the World Health Organization (WHO) classification - Low and Intermediate-1 risk categories MDS using the IPSS (International Prognostic Scoring System)Xx_NEWLINE_xXDocumented AML by peripheral blood or bone marrow analyses meeting World Health Organization (WHO) criteria, excluding patients with acute promyelocytic leukemia (APL)Xx_NEWLINE_xXEpendymoma (World Health Organization [WHO] grade II) or anaplastic ependymoma (WHO grade III) that has relapsed or become refractory to standard therapy; patients must have had histologic verification of their malignancy at original diagnosis or time of recurrenceXx_NEWLINE_xXDiagnosis of acute lymphoblastic leukemia or lymphoblastic lymphoma as defined by the World Health OrganizationXx_NEWLINE_xXDiagnosis of de novo or secondary myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia, as defined by the 2008 World Health Organization classification systemXx_NEWLINE_xXA diagnosis of acute promyelocytic leukemia as defined by the 2008 World Health Organization classification systemXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of glioblastoma multiforme (GBM) or anaplastic glioma, World Health Organization (WHO) grade 3 or 4Xx_NEWLINE_xXHave an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria with ?20% bone marrow blasts based on histology or flow cytometryXx_NEWLINE_xXSubject has documented, histologically locally confirmed, previously untreated CD20+ DLBCL (NOS) per World Health Organization (WHO) classifications (Swerdlow, 2008).Xx_NEWLINE_xXA pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification that is progressing.Xx_NEWLINE_xXRAEB-1 per World Health Organization (WHO) MDS criteria (5% to <10% BM blasts)Xx_NEWLINE_xXPatients must have refractory, progressive or recurrent confirmed low-grade glioma (World Health Organization [WHO] grade I or II) that was confirmed histologically at initial diagnosisXx_NEWLINE_xXWorld Health Organization (WHO) performance status equal to 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.Xx_NEWLINE_xXChronic myelomonocytic leukemia (CMML) should be classified as:\r\n* CMML-1 or CMML-2 based on World Health Organization (WHO) classification of 2008Xx_NEWLINE_xXPatients must have a newly diagnosed or recurrent World Health Organization (WHO) grade II astrocytoma, oligoastrocytoma or oligodendroglioma that has been histologically confirmed by prior biopsy or surgical resection; if the pathological diagnosis was made outside of University of California San Francisco (UCSF), the pathology must be reviewed and confirmed at UCSFXx_NEWLINE_xXPatients must have a histologic diagnosis of meningioma, World Health Organization (WHO) grade 2 or 3 (atypical or anaplastic)Xx_NEWLINE_xXDiagnosis of CMML as defined by the World Health Organization (WHO) criteria.Xx_NEWLINE_xXDiagnosis of T-acute lymphoblastic leukemia/ lymphoblastic lymphoma according to World Health Organization (WHO) criteria which has relapsed or is refractory to chemotherapyXx_NEWLINE_xXHistologically confirmed atypical meningioma, World Health Organization (WHO) grade II, Simpson grade 4-5 that has been either subtotally resected or biopsied; ORXx_NEWLINE_xXRR DLBCL per the 2008 World Health Organization (WHO) classification of hematopoietic and lymphoid tumors (Swerdlow et al, 2008).Xx_NEWLINE_xXPathological criteria - patients must have a newly diagnosed or recurrent World Health Organization (WHO) grade II glioma (defined as an astrocytoma, oligodendroglioma, or oligoastrocytoma) that is to be histologically confirmed by clinically indicated resection; if patients have already undergone biopsy and have pathologic diagnosis of WHO grade II glioma, pathology must be reviewed and confirmed at University of California San Francisco (UCSF)Xx_NEWLINE_xXDiagnosis of a b-cell malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).Xx_NEWLINE_xXA diagnosis of recurrent, persistent, or progressive acute myelogenous leukemia (AML), defined as >= 5% blasts in a patient with known prior history of AML, or recurrent, persistent, or progressive myelodysplastic syndrome (MDS) according to World Health Organization (WHO) criteriaXx_NEWLINE_xXPatients must have a clinical and histopathologic diagnosis of diffuse astrocytoma (World Health Organization, WHO, grade II, III or IV astrocytoma), have completed > 80% of prescribed concurrent radiation therapy and adjuvant temozolomide without Common Terminology Criteria for Adverse Events (CTCAE) grade 4 leukopenia, neutropenia, or thrombocytopenia, and be greater than 7 months from the time of completion of concurrent chemoradiotherapy, with stable disease by neuroimagingXx_NEWLINE_xXPatients must have histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's disease (World Health Organization [WHO] criteria) (Phase I)Xx_NEWLINE_xXWorld Health Organization (WHO)-confirmed acute myeloid leukemia (AML)Xx_NEWLINE_xXPatient must have a documented diagnosis of myelodysplastic syndrome (MDS) of at least three months duration (MDS duration >= 3 months) according to World Health Organization (WHO) criteria or non-proliferative chronic myelomonocytic leukemia (CMML) (white blood cells [WBC] =< 12,000/L)Xx_NEWLINE_xXSubjects must have pathologically confirmed low grade glioma with histologic subtypes interpreted as World Health Organization (WHO) grade I and II including:\r\n* Juvenile pilocytic astrocytoma (JPA) \r\n* Pleomorphic JPA \r\n* Diffuse astrocytoma (fibrillary, gemistocytic, giant cell, or pleomorphic xanthoastrocytoma)\r\n* Subependymal giant cell astrocytoma (SEGA)\r\n* Low grade oligoastrocytoma\r\n* Low grade oligodendroglioma\r\n* Pilomyxoid astrocytoma\r\n* Low grade glioma not otherwise specified (NOS)Xx_NEWLINE_xXPatients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV gliomaXx_NEWLINE_xXSubject must have confirmation of non-acute promyelocytic leukemia (APL) AML by World Health Organization (WHO) criteria and be ineligible or unwilling to undergo treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidities or other factorsXx_NEWLINE_xXHave a histologically proven well-differentiated neuroendocrine tumor (World Health Organization [WHO] grade 1, grade 2, or morphologically and/or clinically well-differentiated grade 3)Xx_NEWLINE_xXan established, confirmed diagnosis of AML by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3; andXx_NEWLINE_xXHistologically confirmed diagnosis of World Health Organization grade IV malignant gliomaXx_NEWLINE_xXAML patients with prior history of MDS or CMML who received therapy for the MDS or CMML and progressed to AML, are eligible at the time of diagnosis of AML regardless of any prior therapy for MDS; the World Health Organization (WHO) classification will be used for AMLXx_NEWLINE_xXPatients must have MDS, or MDS/MPN overlap defined by 2016 World Health Organization (WHO) criteria; both newly diagnosed or previously treated MDS or MDS/MPN patients are eligible as long as the patient has never received prior treatment with azacitidine or decitabineXx_NEWLINE_xXPreviously untreated AML (de novo or secondary) defined according to World Health Organization (WHO) criteria, excluding APL [AML with t(15;17)], with locally documented IDH1 and/or IDH2 gene mutation scheduled for induction therapy followed by consolidation therapy. Secondary AML is defined as AML arising after myelodysplastic syndromes (MDSs) or other antecedent hematologic disorders (AHDs) or AML arising after exposure to genotoxic injury including radiation and/or chemotherapy. Subjects may have had previous treatment for MDS or other AHD, including hypomethylating agents (HMAs), provided that the last dose of administration is ? 14 days prior to study drug initiationXx_NEWLINE_xXParticipant must have confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, previously untreated and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due age or comorbidities.Xx_NEWLINE_xXWorld Health Organization (WHO)-defined acute lymphoblastic leukemia and either:\r\n* Relapsed after achieving remission\r\n* Refractory to therapy\r\n* Newly diagnosed and ineligible for intensive chemotherapy induction\r\nNote: patients with T lineage and B lineage ALL are eligible for this trial; likewise, patients with Philadelphia chromosome positive (Ph+) (as long as they are not candidate for other therapies for Ph+) and Ph- ALL are eligibleXx_NEWLINE_xXHistopathological evidence of glioblastoma or gliosarcoma, World Health Organization (WHO) grade IVXx_NEWLINE_xXWorld Health Organization (WHO)-confirmed AML, other than acute promyelocytic leukemia (APL), with no standard treatment options availableXx_NEWLINE_xXA pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification.Xx_NEWLINE_xXMust have pathologically documented, and definitively diagnosed World Health Organization (WHO) grade 4, glioblastomaXx_NEWLINE_xXHas a diagnosis of acute promyelocytic leukemia (APL) as defined by the World Health OrganizationXx_NEWLINE_xXFirst disease progression or disease recurrence (>= 1 cm and =< 5 cm) of a partially or completely resectable, supratentorial World Health Organization (WHO) grade IV malignant glioma (GBM or gliosarcoma) based on imaging studies with measurable diseaseXx_NEWLINE_xXDiagnosis of recurrent or progressive histologically confirmed World Health Organization (WHO) grade I-III meningioma which has failed maximal safe resection and radiation therapyXx_NEWLINE_xXHas experienced clinical benefit from an EGFR TKI, followed by systemic progression (Response Evaluation Criteria in Solid Tumors [RECIST version 1.1] or World Health Organization [WHO]) while on continuous treatment with an EGFR TKI.Xx_NEWLINE_xXDiagnosis of AML by World Health Organization (WHO) criteria. Patients with high risk myelodysplastic syndrome (MDS) as defined by the presence of >= 10% blasts are also eligible at the discretion of the principal investigatorXx_NEWLINE_xXPatients with a diagnosis BPDCN according to World Health Organization (WHO) classification confirmed by hematopathology;Xx_NEWLINE_xXPatients must have histologically confirmed ND or R/R PTCL defined according to the 2016 World Health Organization (WHO) classification criteria, with no accepted curative options\r\n* Patients with extranodal natural killer (NK)/T-cell lymphoma may only be allocated to treatment Arm DXx_NEWLINE_xXParticipant must have histological confirmation of Acute Myeloid Leukemia (AML) by World Health Organization criteria, be ineligible for intensive induction chemotherapy and either be:Xx_NEWLINE_xXPatients must have a recurrent supratentorial WHO grade III malignant glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, ependymoma) or WHO grade IV malignant glioma (glioblastoma, gliosarcoma) based on imaging studies with measurable disease (>= 1 cm and =< 5.5 cm of contrast-enhancing tumor); the prior histopathology must be consistent with a World Health Organization (WHO) grade III or IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designee; there is no standard of care treatment for children with grade III/IV gliomas; patients must have completed first-line treatments including surgical procedure and a minimum of 54Gy of radiation prior to participating in this trialXx_NEWLINE_xXHave pathologically-proven GB, gliosarcoma (World Health Organization [WHO] IV), or anaplastic astrocytoma (WHO III) in recurrence after treatment with bevacizumabXx_NEWLINE_xXHistologically confirmed diagnosis of malignant glioma by enrolling institution:\r\n* World Health Organization (WHO) grade IV tumors (glioblastoma [GBM] or its variants)\r\n* WHO grade III anaplastic astrocytoma or oligodendroglial tumors or\r\n* WHO grade II gliomas, if magnetic resonance imaging (MRI) shows contrast enhancementXx_NEWLINE_xXHave histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is madeXx_NEWLINE_xXHistologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteriaXx_NEWLINE_xXPatients must have a recurrent supratentorial WHO grade IV malignant glioma based on imaging studies with measurable disease (>= 1 cm and =< 5.5 cm of contrast-enhancing tumor); prior histopathology consistent with a World Health Organization (WHO) grade IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designateXx_NEWLINE_xXDiagnosis of MDS as defined by the World Health Organization (WHO) diagnostic criteriaXx_NEWLINE_xXSubjects must have IPSS-R high or very high risk myelodysplastic syndromes (MDS) by World Health Organization (WHO) classificationXx_NEWLINE_xXAML according to world health organization (WHO) criteria (i.e. bone marrow blasts >20%)Xx_NEWLINE_xXTumor size at least 2 cm in one dimension by clinical or radiographic exam (World Health Organization [WHO] criteria); patients with histologically confirmed palpable lymph nodes may be enrolled regardless of breast tumor sizeXx_NEWLINE_xXPatients with relapsed or refractory high grade glioma (HGG) defined was histologically confirmed World Health Organization (WHO) grade III or WHO grade IV glioma (i.e. glioblastoma multiforme or anaplastic astrocytoma); patients must have had histologic verification of malignancy at original diagnosis or relapse; metastatic disease to the spine is eligible; patients may be in first, second, or third relapse; subjects with intrinsic brain stem gliomas may be eligible if histologically confirmed; please contact study chair prior to enrollmentXx_NEWLINE_xXDiagnosis of AML based on 2008 World Health Organization (WHO) criteria; AML may be de novo, following a prior hematologic disorder, including MDS or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-relatedXx_NEWLINE_xXPHASE II: Patients must have histologically confirmed R/R NHL (as defined by World Health Organization [WHO] criteria); in addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies; patients with DLBCL will be eligible if there is no available standard therapyXx_NEWLINE_xXNewly diagnosed, histologically-confirmed supratentorial World Health Organization (WHO) grade IV gliomas including glioblastoma (all variants) and gliosarcomaXx_NEWLINE_xXPatients with World Health Organization (WHO) class III or IV pulmonary hypertensionXx_NEWLINE_xXPatients must have a prior diagnosis of grade IV glioma (glioblastoma) per 2016 World Health Organization (WHO) criteria, that has progressed after standard radiotherapy (RT) and temozolomide (TMZ) (Note: Pathology will need to be reviewed locally but registration can occur based on pathology report)Xx_NEWLINE_xXHistologically documented diagnosis (based on the 2008 World Health Organization [WHO] Classification) of one of the following:Xx_NEWLINE_xXPathologically documented, and definitively diagnosed recurrent World Health Organization (WHO) Grade IV astrocytoma (GBM).Xx_NEWLINE_xXNewly diagnosed disease with either a diagnosis of “high-risk” MDS (>= 10% blasts in marrow or blood), high-risk myeloproliferative neoplasm (MPN; >= 10% blasts in blood or bone marrow), or AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO) classification; patients with biphenotypic AML are eligible; such “high-risk” MDS or MPN have natural history much closer to AML than to lower risk MDS or MPN and have responded similarly to “AML-type” therapyXx_NEWLINE_xXPatients must have histologically confirmed initial diagnosis of primary intracranial World Health Organization (WHO) Grade IV malignant glioma (glioblastoma, GBM), now recurrent. Patients with recurrent disease whose initial diagnostic pathology confirmed glioblastoma will not need re-biopsy. Alternately, patients with prior intracranial low-grade glioma or anaplastic glioma will be eligible, if histologic assessment demonstrates transformation to GBM (first diagnosis of secondary GBM).Xx_NEWLINE_xXDiagnosis of GBM (World Health Organization [WHO] grade IV); patients who are participating in the optional pre-operative pharmacokinetic study may have presumed GBM based on clinical/radiological findings; however, patient must have histologically confirmed GBM before continuing to receive DSF with concurrent RT/TMZXx_NEWLINE_xXNewly diagnosed, previously untreated chronic phase chronic myeloid leukemia (CP-CML) (by World Health Organization [WHO] definition) (hydroxyurea permitted up to 7 days prior to enrollment)Xx_NEWLINE_xXHave a newly diagnosed AML, based on World Health Organization criteria, currently in first (1st) complete remission (CR)/complete remission with incomplete count recovery (CRi) on a bone marrow biopsy performed within 4 weeks of study enrollmentXx_NEWLINE_xXHas a diagnosis of acute promyelocytic leukemia (APL) as defined by the World Health OrganizationXx_NEWLINE_xXDiagnosis of AML and MDS according to World Health Organization (WHO) classification that underwent first allogeneic hematopoietic cell transplant (HSCT) with either peripheral blood or bone marrow as the source of the hematopoietic stem cellsXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed World Health Organization (WHO) grade 4 glioma for which a clinically indicated tumor resection is plannedXx_NEWLINE_xXDiagnosis of AML according to World Health Organization (WHO) 2008 criteria; therapy related AML may be included if in complete response and off treatment for their prior malignancy for more than 2 years; AML arising after documented myeloproliferative disease (MPD) are excludedXx_NEWLINE_xXHistopathologically proven newly-diagnosed, supratentorial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)Xx_NEWLINE_xXPHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will also be eligible if the original histology was lower grade glioma and there is suspected transformation to glioblastoma based on imaging findings; if the final pathology report after resection fails to confirm recurrent glioblastoma or gliosarcoma, the subject will be followed for adverse events (AEs) and survival, but excluded for other primary and secondary objective analysis; the subject will be replacedXx_NEWLINE_xXPHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Have histologically confirmed World Health Organization grade IV glioma (glioblastoma or gliosarcoma)Xx_NEWLINE_xXPHASE I: Have histologically confirmed World Health Organization WHO grade IV glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is madeXx_NEWLINE_xXSubjects must have histologically confirmed diagnosis of World Health Organization (WHO) grade III or IV malignant gliomaXx_NEWLINE_xXHistologically confirmed diagnosis of World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed diagnosis of mycosis fungoides (MF), Sezary syndrome (SS) or primary cutaneous CD30-positive lymphoproliferative disorder, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL) (pc-ALCL) as defined by the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissueXx_NEWLINE_xXPatients must have a diagnosis of acute myeloid leukemia (AML) according to World Health Organization (WHO) criteria; therapy-related and secondary AML (arising after a period of myelodysplastic syndrome [MDS]) allowed; prior treatment for MDS with hypomethylator-based therapy and lenalidomide allowed, but not allowed if used after the diagnosis of AML is made, since enrollment to this study is not for relapsed AMLXx_NEWLINE_xXFor Part 1 of the study, participants must have histopathologically confirmed diagnosis of R/R, DLBCL, FL, MZL/MALT, MCL, or other Sponsor approved NHL subtypes according to the World Health Organization (WHO) classification 2008 for which standard measures do not exist or are no longer effective.Xx_NEWLINE_xXDocumented/confirmed first/second refractory/relapsed AML using World Health Organization classification, except acute promyelocytic leukemiaXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of World Health Organization (WHO) grade 4 malignant glioma and radiographic evidence of recurrence or disease progression (as defined by the Response Assessment in Neuro-Oncology [RANO] criteria as a greater than 25% increase in the largest bi-dimensional product of enhancement or a new enhancing lesion, or a significant increase in T2-weighted-Fluid-Attenuated Inversion Recovery [T2/FLAIR] abnormality without another co-morbid cause)Xx_NEWLINE_xXWorld Health Organization (WHO) performance status 0-2Xx_NEWLINE_xXWorld Health Organization Performance Status of 0 to 1.Xx_NEWLINE_xXPatients must have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic NeoplasmsXx_NEWLINE_xXDiagnosis of 1) AML (World Health Organization [WHO] classification definition of >= 20% blasts), or 2) high risk MDS (defined as the presence of 10% blasts)Xx_NEWLINE_xXHistory of AML according to World Health Organization (WHO) classificationXx_NEWLINE_xXPatients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who received therapy for the MDS or CMML and progress to AML are eligible at the time of diagnosis of AML regardless any prior therapy for AML; the World Health Organization (WHO) classification will be used for AML; prior therapy for MDS or CMML will not be considered as a prior therapy for AMLXx_NEWLINE_xXHistologic confirmation of thymic carcinoma (World Health Organization [WHO] classification)Xx_NEWLINE_xXMature T-cell non-Hodgkin lymphoma (see World Health Organization [WHO] for specific malignancies)\r\n* First CR\r\n* Relapse after greater than or equal to 1 prior regimenXx_NEWLINE_xXHistologic confirmation is not required for this if the patient has neurofibromatosis type 1 (NF-1) with magnetic resonance imaging (MRI) findings consistent with optic pathway glioma or juvenile pilocytic astrocytoma (JPA); any other tumors will need histological confirmation, either at the time of diagnosis or at the time of recurrence; the histological diagnosis includes World Health Organization (WHO) grade I JPAXx_NEWLINE_xXMust have a histopathologically documented diagnosis of primary or secondary AML (excluding acute promyelocytic leukemia), as defined by World Health Organization (WHO) criteria (Jaffe et al, 2001), for whom no standard therapies are anticipated to result in a durable remission according to the clinical judgment of the principal investigator, or who refuses standard therapies (phase 1b and 2).Xx_NEWLINE_xXWorld Health Organization (WHO) performance status 0-2Xx_NEWLINE_xXDiagnosis of AML (World Health Organization [WHO] classification definition of >= to 20% blasts)Xx_NEWLINE_xXPART 1: Disease criteria\r\n* Diagnosis of primary MF (PMF) as defined by the 2008 World Health Organization classification system or diagnosis of secondary MF as defined by the International Working Group (IWG) for Myeloproliferative Neoplasms Research and Treatment criteria\r\n* Patients meeting the criteria for intermediate-1, intermediate-2 or high-risk disease by the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus scoring systemXx_NEWLINE_xXHistologically confirmed diagnosis of a myelodysplastic syndrome, meeting criteria for any subtype in the French-American-British (FAB) or World Health Organization (WHO) classification systems with any International Prognostic Scoring System (IPSS) scoreXx_NEWLINE_xXDiagnosis of myelodysplastic syndrome (MDS) confirmed within 10 weeks prior to study entry according to World Health Organization (WHO) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplantXx_NEWLINE_xXARM 2 - BPDCN: Research participants with a diagnosis of BPDCN, according to World Health Organization (WHO) classification by hematopathology, who underwent at least 1 line of systemic therapy for BPDCN and who have persistent or recurrent disease in at least one of the following are eligible: peripheral blood, bone marrow, lymph nodes, spleen, cutaneous lesions or other sites OR participant who are at high risk for disease recurrenceXx_NEWLINE_xXTumor size at least 2 cm in one dimension by clinical or radiographic exam (World Health Organization [WHO] criteria); patients with palpable lymph nodes may be enrolled regardless of tumor sizeXx_NEWLINE_xXHistologically confirmed glioblastoma multiforme, World Health Organization (WHO) grade IV astrocytomaXx_NEWLINE_xXPHASE I\r\n* Primary or secondary AML according to World Health Organization (WHO) classification, with relapsed or refractory disease or newly diagnosed older subjects (greater than or equal to 65 years of age), not candidates for intensive chemotherapy\r\n* Subjects with myelodysplastic syndrome (MDS), International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (refractory anemia with excess blasts [RAEB]-2 only, i.e. greater than or equal to 10% blast) who are resistant or intolerant to standard treatment and are not candidates for transplantation \r\n* Subjects with acute lymphoblastic leukemia (ALL), relapsed, refractory or intolerant to standard treatment and for whom no effective treatment options are availableXx_NEWLINE_xXHistologic diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)Xx_NEWLINE_xXDiagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteriaXx_NEWLINE_xXHistologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)Xx_NEWLINE_xXHistologically confirmed mantle cell lymphoma classified according to World Health Organization (WHO) criteria confirmed at MSKCCXx_NEWLINE_xXHistory of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts ?20%).Xx_NEWLINE_xXHistologic evidence of Well differentiated Neuroendocrine tumors (NETs) of the lung (typical and atypical according to the World Health Organisation (WHO criteria), evaluated locally)Xx_NEWLINE_xXHave an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M3) with a bone marrow of >5% blasts based on histology or flow cytometryXx_NEWLINE_xXParticipants must have either:\r\n* Histologically confirmed low-grade gliomas as defined by, World Health Organization (WHO) classification I-II/IV; these tumors can include astrocytomas, oligodendrogliomas, and mixed variants such as oligoastrocytomas; WHO classification is not required when pathology can only confirm that glioma is low grade; Karnofsky performance status (KPS) must be >= 70 OR\r\n* Histologically confirmed favorable anaplastic glioma as defined by WHO grade III with either or both isocitrate dehydrogenase 1 (IDH1) mutation or 1p/19q codeletion; in addition, these participants must have a KPS >= 70Xx_NEWLINE_xXWorld Health Organization (WHO) performance status =< 2Xx_NEWLINE_xXMyelodysplastic syndrome as defined by World Health Organization (WHO) criteriaXx_NEWLINE_xXHistologically confirmed diagnosis of World Health Organization (WHO) I-III meningiomas and hemangiopericytomasXx_NEWLINE_xXSubjects with pathologic evidence of an anaplastic oligodendroglioma or mixed glioma (i.e. oligoastrocytoma) are eligible; histopathologic diagnosis will be made using World Health Organization classification criteria; to qualify as a mixed tumor there must be a minimum of 25% oligodendroglial elementXx_NEWLINE_xXDiagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRTXx_NEWLINE_xXPathologically confirmed relapsed or refractory (primary refractory and relapsed refractory) Acute Myeloid Leukemia (AML) (defined by World Health Organization (WHO) criteria) for which no further conventional therapy is suitable for the patient, or confirmed myelodysplastic syndrome defined according to WHO classification, with an International Prognostic Scoring System (IPSS) risk category of intermediate-2 or high risk, that is relapsed, refractory or intolerant to conventional therapy within 3 weeks of registration.Xx_NEWLINE_xXNewly diagnosed glioblastoma (GBM) histologically proven, World Health Organization (WHO) grade IV GBM or WHO grade IV gliosarcoma.Xx_NEWLINE_xX3. Morphologically documented relapsed/refractory AML as defined by World Health Organization (WHO) criteria after at least 1 prior therapy for AML with the exception of hydroxyurea, and not felt to have curative treatment options per treating physician, or the patients themselves are unwilling to consider curative treatment options.Xx_NEWLINE_xXDiagnosis of mature B-cell ALL (Burkitt’s leukemia) according to World Health Organization (WHO) classification, or lymphoid blast crisis of chronic myelogenous leukemia (CML)Xx_NEWLINE_xXConfirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classificationXx_NEWLINE_xXConfirmed diagnosis of AML according to World Health Organization (WHO) 2016 classificationXx_NEWLINE_xXNewly diagnosed, histologically-confirmed supratentorial World Health Organization (WHO) grade IV gliomas including glioblastoma (all variants) and gliosarcoma.Xx_NEWLINE_xXHave histologically confirmed World Health Organization grade IV glioma (glioblastoma [GB] or gliosarcoma).Xx_NEWLINE_xXNewly diagnosed histologically confirmed unmethylated glioblastoma multiforme (World Health Organization [WHO] grade IV). Patients with secondary glioblastoma, in particular those who are IDH1 or IDH2 mutant, will not be excluded. Unmethylated MGMT must be confirmed by a polymerase chain reaction (PCR)-based assay.Xx_NEWLINE_xXHistologically proven, newly diagnosed World Health Organization (WHO) grade III or IV astrocytoma that has a methylated MGMT promoter as assessed by the standardized institutional analysisXx_NEWLINE_xXHistologically-confirmed intracranial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) with evidence of clinical and radiographic (computed tomography [CT] or MRI brain) tumor progression (need not be biopsy proven)Xx_NEWLINE_xXHistologically or cytologically documented diagnosis of MDS according to the World Health Organization (WHO) classification (Vardiman 2009, Arber 2016) with >5% and <20% bone marrow blasts by morphology and a peripheral white blood cell (WBC) count of <20,000/?LXx_NEWLINE_xXCytologically or histologically confirmed diagnosis of MDS or CMML according to the 2008 World Health Organization (WHO) classification.Xx_NEWLINE_xXHistologically proven advanced MPM of biphasic or sarcomatoid histology. Biphasic MPM is defined using the World Health Organization's international histological classification of tumors as containing an epithelial and a sarcomatoid component with each component comprising at least 10% of the tumorXx_NEWLINE_xXDiagnosis of AML per World Health Organization criteriaXx_NEWLINE_xXThe subject must have histological confirmation of GBM (World Health Organization [WHO] grade IV)Xx_NEWLINE_xXA diagnosis of acute myeloid leukemia (AML) according to the World Health Organization 2008 criteria with relapsed or refractory disease and ineligible for or have exhausted standard therapeutic optionsXx_NEWLINE_xXSubject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:Xx_NEWLINE_xXHistologically confirmed diagnosis of World Health Organization grade III or IV malignant gliomaXx_NEWLINE_xXMorphologically confirmed new diagnosis of AML in accordance with World Health Organization (WHO) diagnostic criteriaXx_NEWLINE_xXPathologically confirmed World Health Organization (WHO) grade IV glioblastoma or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma) with adequate tumor material for genomic sequencing; participants will be eligible if the original diagnosis was a lower grade glioma and a subsequent histologic diagnosis of glioblastoma or its variants was made, and they received no prior therapy other than surgeryXx_NEWLINE_xXDiagnosis of MDS according to World Health Organization (WHO) criteria or French-American-British (FAB) classification that must be confirmed by bone marrow (BM) aspirate and/or biopsy within 6 weeks prior to Screening.Xx_NEWLINE_xXNewly diagnosed and histologically confirmed supratentorial World Health Organization (WHO) Grade IV astrocytoma status-post maximally achievable resectionXx_NEWLINE_xXHistopathologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) following either a surgical resection or biopsyXx_NEWLINE_xXPatients must have histologically or cytologically confirmed AML according to the World Health Organization (WHO) criteriaXx_NEWLINE_xXSubjects with a prior diagnosis of AML (excluding acute promyelocytic leukemia) based on World Health Organization classification who did not achieve complete response (CR) with their previous therapy or who have relapsed after achieving a complete response (CR) are eligible; any number of relapses will be eligibleXx_NEWLINE_xXHigh risk myelodysplastic syndrome (MDS)\r\n* Intermediate II and high risk by International Prognostic Scoring System (IPSS)\r\n* Intermediate, high, or very high by World Health Organization (WHO) classification-based Prognostic Scoring System (WPSS)\r\n* Transfusion dependent\r\n* Therapy-related MDS or MDS evolved from previous hematological disorder (excepting myelofibrosis)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed acute myeloid leukemia (AML) by World Health Organization (WHO) criteria in the blood and/or marrow AND age >= 60 and not candidates/refuse standard induction treatment OR who have one of the following: poor risk cytogenetics, AML following antecedent hematologic disorder, or therapy-related AMLXx_NEWLINE_xXDiagnosis of acute myeloid leukemia (AML) as defined by the World Health OrganizationXx_NEWLINE_xXAll patients must have a pathologically confirmed diagnosis of classical Hodgkin's lymphoma (HL) as outlined in the World Health Organization (WHO) classification system of lymphoid tumors; patients with nodular lymphocyte-predominant HL (NLPHL) are not eligibleXx_NEWLINE_xXHistologically confirmed follicular non-Hodgkin lymphoma, World Health Organization (WHO) classification grade 1, 2, or 3a (> 15 centroblasts per high-power field with centrocytes present)\r\n* Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies\r\n* Fine-needle aspirates are not acceptable\r\n* Failure to submit pathology within 60 days of patient registration will be considered a major protocol violationXx_NEWLINE_xXPatients with newly diagnosed or recurrent glioma of World Health Organization (WHO) grade III or IV (anaplastic astrocytoma [AA], anaplastic astro-oligodendroglioma [AO], or glioblastoma [GBM]) will be eligible for this protocolXx_NEWLINE_xXDocumented diagnosis of primary myelofibrosis according to World Health Organization (WHO) criteria or post polycythemia vera (PV) myelofibrosis or post essential thrombocythemia (ET) myelofibrosis as per IWG-MRT criteriaXx_NEWLINE_xXA diagnosis of ET or PV shall be made in accordance with the World Health Organization (WHO) (2008) criteria (Swerdlow 2008)Xx_NEWLINE_xXMorphologically documented primary Acute Myeloid Leukemia (AML) or AML secondary to Myelodysplastic Syndrome (MDS), as defined by World Health Organization (WHO) criteria, as determined by pathology review at the study site.Xx_NEWLINE_xX1d. Glioblastoma -Enrollment Completed Have histologically confirmed World Health Organization Grade IV malignant glioma (glioblastoma).Xx_NEWLINE_xXDiagnosis of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as documented by medical records and with histology based on criteria established by The World Health Organization (WHO):Xx_NEWLINE_xXRelapsed or refractory CD25-positive AML [per World Health Organization (WHO)].Xx_NEWLINE_xXRelapsed or refractory CD25-positive ALL [per World Health Organization (WHO)].Xx_NEWLINE_xXDiagnosis of a hematologic malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).Xx_NEWLINE_xXDiagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and with histology based on criteria established by the World Health OrganizationXx_NEWLINE_xXAge ? 18 years at the time of signing the informed consent form. 8. Central confirmation of diagnosis of previously untreated primary or secondary Myelodysplastic syndromes (MDS) as per World Health Organization (WHO) classification. Results of central pathology review are required prior to receiving the first dose of IP.Xx_NEWLINE_xXAMKL PATIENTS: Patients must have a confirmed diagnosis (by blood or bone marrow) of relapsed/refractory acute megakaryoblastic leukemia (AMKL), as defined by World Health Organization (WHO) criteria\r\n* NOTE: if diagnosis was performed an outside facility, a copy of the report is sufficient for registration purposes; however, local pathology review at one of the main sites should still be obtainedXx_NEWLINE_xXPatient must have documented diagnosis of MDS lasting at least three months (MDS duration >= 3 months) according to World Health Organization (WHO) criteria or non-proliferative chronic myelomonocytic leukemia (CMML) (white blood cell [WBC] < 12,000/mcL)Xx_NEWLINE_xXMDS: MDS classifiable by the World Health Organization (WHO) system as RA, RARS, refractory cytopenia with multilineage dysplasia (RCMD), RCMD and ringed sideroblasts (RCMD-RS) or RAEBXx_NEWLINE_xXMale or female patients, ages 18 years or older with pathologically confirmed relapsed or refractory B-cell lineage NHL who have failed or are intolerant to established therapy, or for whom no other treatment options are available. Refractory or relapsed B-cell NHL (per World health Organization [WHO] Classification system)Xx_NEWLINE_xXMyelodysplastic Syndrome (MDS) according to the World Health Organization (WHO) 2008 classificationXx_NEWLINE_xXHistologic documentation: newly diagnosed World Health Organization (WHO) grade IV intracranial glioblastoma or gliosarcoma; GBM with oligodendroglial features are NOT PERMITTED in this study if they are 1p19q codeleted; sites submitting GBM with oligodendroglial features will be asked to provide results of 1p/19q codeletion statusXx_NEWLINE_xXHistologically or cytologically confirmed recurrent or metastatic SCCHN\r\n* All primary sites are eligible excluding World Health Organization (WHO) type III or Epstein–Barr virus (EBV) nasopharyngeal (WHO type I and WHO type II allowed as long as they are EBV negative)Xx_NEWLINE_xXDiagnosis of MDS, CMML, or RAEB-t/non-proliferative AML (as defined by 20-30% BMBL, WBC ? 25,000 x 10^9/L and stable for at least 4 weeks without intervention) according to World Health Organization (WHO) criteria or French American British (FAB) classification either previously treated or previously untreated. The diagnosis must be confirmed via BM aspirate and/or biopsy within 6 weeks prior to Screening. Note: patients with RAEB-t/non-proliferative AML (as defined by 20-30% BMBL, WBC ? 25,000 x 10^9/L and stable for at least 4 weeks without intervention) are not eligible for the Phase II Part 1 RPTD component of the study and patients with CMML will not be eligible for Phase II Part 2 Expansion of the study.Xx_NEWLINE_xXWorld Health Organization (WHO) risk score 0-6Xx_NEWLINE_xXNewly diagnosed histologically confirmed glioblastoma multiforme (World Health Organization [WHO] grade IV); patients with secondary glioblastoma, in particular those who are IDH1 or IDH2 mutant, will not be excludedXx_NEWLINE_xXA diagnosis of SM per 2008 World Health Organization (WHO) criteria; patients with ASM and MCL, or SM-AHNMD are required to have at least one of the eligible organ damage findings as defined by the international consensus response criteria (Gotlib, 2013)Xx_NEWLINE_xXPatients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who received therapy for the MDS or CMML and progress to AML are eligible at the time of diagnosis of AML regardless any prior therapy for AML; the World Health Organization (WHO) classification will be used for AMLXx_NEWLINE_xXHistologically confirmed diagnosis of World Health Organization (WHO) grade III (except anaplastic oligodendroglioma) or IV malignant gliomaXx_NEWLINE_xXPathological diagnosis of AML according to World Health Organization (WHO) criteria (with at least 20% blasts in the peripheral blood or bone marrow): newly diagnosed de novo AML; except for acute promyelocytic leukemia (APL); newly diagnosed secondary AML, defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes [MDS], myeloproliferative disease [MPD] or history of cytotoxic treatment for non-hematologic malignancy) or apparent de novo AML with MDS-associated karyotypeXx_NEWLINE_xXSubjects must have relapsed/refractory AML by world health organization (WHO) classification for which no standard therapies are available or anticipated to result in a durable remission. French- American- British system (FAB) subtype M3 will be excluded.Xx_NEWLINE_xXFor patients with newly diagnosed disease: diagnosis of “high-risk” myelodysplastic syndrome (MDS) (>= 10% blasts) or AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO) classification; for patients with relapsed/refractory disease: prior diagnosis of “high-risk” MDS or non-APL AML, with relapsed/refractory disease according to standard criteria requiring first or subsequent salvage therapy; patients with biphenotypic AML are eligibleXx_NEWLINE_xXA diagnosis of systemic mastocytosis (SM) per 2008 World Health Organization (WHO) CriteriaXx_NEWLINE_xXPatients must have histologic verifications of a glioblastoma multiforme, anaplastic astrocytoma, gliomatosis cerebri (World Health Organization [WHO] grade III or IV glioma with diffuse parenchymal and/or leptomeningeal involvement), or gliosarcoma at the time of study enrollmentXx_NEWLINE_xXSubject has a diagnosis of previously-untreated AML according to World Health Organization (WHO) classification [Swerdlow et al, 2008] as determined by pathology review at the treating institution.Xx_NEWLINE_xXIn Part 1, diagnosis of myelodysplastic syndrome (MDS) according to World Health Organization (WHO) criteriaXx_NEWLINE_xXWorld Health Organization (WHO) performance status of 0, 1, or 2Xx_NEWLINE_xXPerformance status (World Health Organization [WHO] scale) < 2Xx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of primary myelofibrosis (PMF), post-polycythemia vera (post-PV) myelofibrosis (MF), or post-essential thrombocythemia (post-ET) MF using World Health Organization CriteriaXx_NEWLINE_xXNewly diagnosed and recurrent high grade gliomas (World Health Organization [WHO] grades III & IV) and high risk WHO grade II gliomas who are to begin treatment with monthly high dose temozolomide therapyXx_NEWLINE_xXUntreated, histological confirmed acute myeloid leukemia (AML) based on World Health Organization (WHO) 2008 criteria with either/or both:\r\n* FLT3 ITD mutation\r\n* FLT3 TKD mutationXx_NEWLINE_xXNon-squamous cell carcinomas of the head and neck region i.e. nasopharyngeal carcinoma (World Health Organization [WHO] type II and III) and salivary gland carcinomasXx_NEWLINE_xXWorld Health Organization (WHO) performance score of 0 to 1 with life expectancy of at least 3 monthsXx_NEWLINE_xXPathologically confirmed diagnosis of glioblastoma multiforme (GBM); or World Health Organization (WHO) grade IV (gliosarcoma)Xx_NEWLINE_xXDiagnosis of CLL meeting criteria established in the World Health Organization (WHO) classification of hematologic disordersXx_NEWLINE_xXHistologically confirmed AML (defined using World Health Organization [WHO] criteria) with one of the following:\r\n* Primary refractory disease following =< 2 cycles of induction chemotherapy, or\r\n* First relapse with no prior unsuccessful salvage chemotherapy, or\r\n* Relapsed or refractory to hypomethylating agent, defined as a lack of response, disease progression, loss of response, or intolerance as deemed by the study investigatorXx_NEWLINE_xXJAK2V617F-positive PV or JAK2V617F-positive ET (confirmed by World Health Organization [WHO] diagnostic criteria)Xx_NEWLINE_xXWorld Health Organization (WHO) Performance Status of 0 or 1Xx_NEWLINE_xXHave histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is madeXx_NEWLINE_xXHave histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is madeXx_NEWLINE_xXWorld Health Organization Performance Status of 0 to 1 with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeksXx_NEWLINE_xXPatients must have histologically confirmed HNSCC, from any primary site; nasopharyngeal carcinoma, World Health Organization [WHO] type I (keratinizing), will be included; squamous cell carcinoma of unknown primary, clearly related to the head and neck, will be includedXx_NEWLINE_xXPatients must have measurable non-visceral lesion(s) that are evaluable by the modified World Health Organization (mWHO) criteria and immune-related response criteria (irRC).Xx_NEWLINE_xXPatients with thymic carcinoma (formerly World Health Organization [WHO] type C)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed mantle cell lymphoma as defined by the World Health Organization; all patients must have either t(11;14) by karyotype or fluorescent in-situ hybridization (FISH) or positive immunohistochemistry for cyclin D1Xx_NEWLINE_xXWorld Health Organization (WHO) performance status 0-1Xx_NEWLINE_xXWorld Health Organisation (WHO) Performance Status of 0 to 1.Xx_NEWLINE_xXWorld Health Organisation (WHO) Performance Status of 0 or 1Xx_NEWLINE_xXSubjects must have their diagnosis of high-risk AML or high-risk MDS confirmed by pathologic review of bone marrow biopsy according to World Health Organization (WHO) guidelinesXx_NEWLINE_xXPathological diagnosis of AML (by World Health Organization [WHO] criteria) or higher risk MDS (includes intermediate [int]-2 and high risk MDS by International Prognostic Scoring System (IPSS) along with one of the following:\r\n* Patients with de novo or secondary MDS with progression/refractoriness after HMA treatment who have not transformed to AML\r\n* Patients with MDS and prior HMA treatment for MDS who transformed to AML \r\n* Patients with AML who are refractory/relapsed after HMA therapy for their AML are eligibleXx_NEWLINE_xXSubjects with a histologically confirmed diagnosis of MDS by French American British (FAB) criteria, including both MDS and refractory anemia with excess blasts in transformation (RAEB-T) (AML with 20-30% blasts and multilineage dysplasia) and chronic myelomonocytic leukemia (CMML) with at least 10% bone marrow blasts by World Health Organization (WHO) classification are eligibleXx_NEWLINE_xXPatients must have tissue confirmation of high grade (World Health Organization [WHO] grade IV) glioma including but not limited to glioblastoma, gliosarcoma, glioblastoma with oligodendroglial features, glioblastoma with primitive neuroectodermal tumor (PNET) featuresXx_NEWLINE_xXDiagnosis of acute myelogenous leukemia (AML) according to World Health Organization (WHO) criteria;Xx_NEWLINE_xXDiagnosis of Myelodysplastic syndrome (MDS) according to WHO classification with refractory anemia with excess blasts (subtype RAEB-1 or RAEB-2), or considered high-risk by the Revised International Prognostic Scoring System (IPSS-R), that is recurrent or refractory, or the subject is intolerant to established therapy known to provide clinical benefit for their condition (i.e., subjects must not be candidates for regimens known to provide clinical benefit), according to the treating physician and with approval of the Medical Monitor. Phase 1/Part 1 Expansion: Arm 1: Relapsed or refractory AML and age greater than or equal to 60 years or any subject with AML regardless of age who has relapsed following a Bone marrow transplant (BMT). Arm 2: Relapsed or refractory AML and age <60 years, excluding subjects with AML who have relapsed following a BMT. Arm 3: Untreated AML and age greater than or equal to 60 years that decline standard of care chemotherapy. Arm 4: Isocitrate dehydrogenase protein, 2 (IDH2)-mutated advanced hematologic malignancies not eligible for Arms 1 to 3. Phase 2: Diagnosis of AML according to World Health Organization (WHO) criteria and disease relapsed or refractory as defined by:Xx_NEWLINE_xXDiagnosis of histologically confirmed GBM (World Health Organization [WHO] grade IV)Xx_NEWLINE_xXSubjects with a histologically confirmed diagnosis of MDS by FAB criteria, including both MDS and RAEB-T (AML with 20-30% blasts and multilineage dysplasia) by World Health Organization (WHO) classification are eligible.Xx_NEWLINE_xXHistologically proven recurrent World Health Organization (WHO) grade II (atypical) or grade III (anaplastic) intracranial supratentorial meningioma; Memorial Sloan-Kettering Cancer Center (MSKCC) central review of histology is not requiredXx_NEWLINE_xXPatients must have a diagnosis of CLL/SLL or B-cell prolymphocytic leukemia, as defined by the World Health Organization (WHO)Xx_NEWLINE_xXHistological diagnosis of: glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) adapted recursive partitioning analysis (RPA) class III, IV, or VXx_NEWLINE_xXNewly diagnosed AML (according to the World Health Organization [WHO] 2008 classification) except t(15;17), including:\r\n* De novo AML\r\n* Secondary AML\r\n* Secondary AML arising from previously diagnosed myelodysplastic syndromes (MDS) or other antecedent hematologic malignancy treated with deoxyribonucleic acid (DNA) methyltransferase inhibitor (DNMTi) (i.e., decitabine or azacitidine)Xx_NEWLINE_xXAge >= 70, or age >= 60 ineligible for treatment with standard induction chemotherapy (based on physician discretion or patient refusal), with a new diagnosis of AML based on World Health Organization classificationXx_NEWLINE_xXUntreated, histological confirmed acute myeloid leukemia (AML) based on World Health Organization (WHO) 2008 criteria with Kit expression (CD 117) of myeloblasts >= 20% by flow cytometry from bone marrow aspirate at diagnosisXx_NEWLINE_xXConfirmed diagnosis of CMML using the World Health Organization (WHO) classificationXx_NEWLINE_xXprimary myelofibrosis (PMF) per the revised World Health Organization (WHO) criteriaXx_NEWLINE_xXPatients must have histologically confirmed newly diagnosed high-grade glioma (World Health Organization [WHO] grade III or IV)Xx_NEWLINE_xXSubject must have histologically documented diagnosis of non-Hodgkin's lymphoma as defined by a B-cell neoplasm in the World Health Organization classification scheme except as noted in exclusion criteria.Xx_NEWLINE_xXPatients must have a World Health Organization performance status =< 2Xx_NEWLINE_xXPatients with World Health Organization performance status of 3 or 4Xx_NEWLINE_xXPatients must have a recurrent supratentorial WHO grade IV malignant glioma based on imaging studies with measurable disease (>= 1 cm and =< 5.5 cm of contrast-enhancing tumor); prior histopathology consistent with a World Health Organization (WHO) grade IV malignant glioma confirmed by the study pathologist, Roger McLendon, or his designateXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of glioblastoma multiforme (GBM) or anaplastic glioma, World Health Organization (WHO) grade 3 or 4Xx_NEWLINE_xXMust have measurable disease by modified World Health Organization (WHO) criteriaXx_NEWLINE_xXDiagnosis of myelodysplastic syndrome (MDS) confirmed within 10 weeks prior to study entry according to World Health Organization (WHO) or French-American-British (FAB) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplantXx_NEWLINE_xXPatients with histologically proven supratentorial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV astrocytoma) will be eligible for this protocol; patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or gliosarcoma is made prior to any definitive treatment (radiotherapy, chemotherapy)Xx_NEWLINE_xXGBM patients only (enrollment plan 1)\r\n* Histologically confirmed glioblastoma multiforme World Health Organization (WHO) grade III-IV with recurrent or progressive disease after standard therapy\r\n* Age 16 years and olderXx_NEWLINE_xXConfirmed diagnosis of MDS using the World Health Organization (WHO) classification or a diagnosis of WHO myelodysplastic/ myeloproliferative neoplasm (MDS/MPN) or MDS refractory anemia with excess blast in transformation (RAEB-t) by French American British (FAB) classification (acute myeloid leukemia [AML] with 20-30% myeloblasts by WHO classification)Xx_NEWLINE_xXHistologically documented Hodgkin lymphoma subclassified according to the World Health Organization (WHO) modification of the Rye Classification and staged according to the modified Ann Arbor Staging Classification system; patients must have clinical stage IA, IB, IIA or IIB; patients with “E” extensions will be eligible if all other criteria have been met; nodular lymphocyte predominant Hodgkin lymphoma is excludedXx_NEWLINE_xXDiagnosis of essential thrombocythemia according to revised World Health Organization (WHO) 2016 criteria.Xx_NEWLINE_xXModerate or severe pulmonary hypertension defined as pulmonary artery systolic pressure (PASP) > 50mm Hg; for those patients where PASP is indeterminate, moderate to severe symptoms of pulmonary hypertension (World Health Organization functional assessment class III or IV) will be used to determine exclusion criteriaXx_NEWLINE_xXHistologically confirmed diagnosis of a recurrent primary World Health Organization (WHO) grade IV malignant glioma (glioblastoma); patients with recurrent disease whose diagnostic pathology confirmed glioblastoma will not need re-biopsy; patients with prior low-grade glioma or anaplastic glioma (anaplastic astrocytoma or anaplastic oligodendroglioma) are eligible if histologic assessment demonstrates transformation to GBMXx_NEWLINE_xXConfirmed diagnosis of non-acute promyelocytic leukemia (APL) AML (World Health Organization [WHO] criteria)Xx_NEWLINE_xXWorld Health Organization (WHO) performance status 0-2Xx_NEWLINE_xXTIER I SUBJECTS: Histologically confirmed follicular lymphoma (grade 1, 2 or 3) by the World Health Organization (WHO) classification; all pathology must be confirmed at either Brigham and Women's Hospital or Massachusetts General Hospital; a repeat biopsy confirming the above histologies must be performed prior to enrollment if there is clinical suspicion that the patient has transformed to a more aggressive lymphomaXx_NEWLINE_xXNewly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL))Xx_NEWLINE_xXSubjects with cytologically/histologically confirmed MDS according to the World Health Organization (WHO) 2008 classification.Xx_NEWLINE_xXPatients with a new diagnosis of histologically confirmed (according to World Health Organization [WHO] classification 2008) acute myeloid leukemia (either primary or secondary AML) are includedXx_NEWLINE_xXPatients must have a previous morphologically confirmed diagnosis of AML based on World Health Organization (WHO) criteriaXx_NEWLINE_xXPatients with a histologically confirmed diagnosis of myelodysplastic syndrome (MDS) by World Health Organization (WHO) classification, and lower-risk MDS as defined by the International Prostate Symptom Score (IPSS) classification (low or intermediate [int]-1 disease) or Revised-International Prostate Symptom Score (R-IPSS) classification (very low or low) are eligible; patients with MDS/myeloproliferative neoplasm (MPD) overlap syndromes including chronic myelomonocytic leukemia (CMML) are also eligible if they have low or int-1 disease per IPSS; patients may have received MDS-directed therapy (i.e. lenalidomide), although patients with prior exposure to hypomethylating agents (e.g. 5-azacitidine or decitabine) are not eligibleXx_NEWLINE_xXPatients must have a history of de novo or therapy-related AML (defined by World Health Organization [WHO] classification of >= 20% bone marrow blasts) or high-risk MDS (defined by International Prognostic Scoring System [IPSS] or Revised International Prognostic Scoring System [IPSS-R])Xx_NEWLINE_xXDiagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteriaXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL, French-American-British [FAB] classification M3 or World Health Organization [WHO] classification of APL with t[15;17][q22;q12]), (progressive multifocal leukoencephalopathy [PML]/retinoic acid receptor alpha [RARa] and variants)Xx_NEWLINE_xXMDS by World Health Organization (WHO) or French-American-British (FAB) classificationXx_NEWLINE_xXPatients eligible include those with diagnosis of AML other than acute promyelocytic leukemia by World Health Organization (WHO) criteria with relapsed disease after induction therapy or refractory to induction chemotherapy, as determined by morphology on bone marrow biopsy; also eligible are patients unwilling to receive standard induction chemotherapyXx_NEWLINE_xXWorld Health Organization (WHO) Performance Status (PS) ? 2Xx_NEWLINE_xXPatient has one of the following peripheral T-cell lymphoma (PTCL) subtypes confirmed by an independent central pathology reviewer, using the Revised European American Lymphoma World Health Organization disease classification:Xx_NEWLINE_xXHistologically confirmed metastatic head and neck squamous cell carcinoma (HNSCC), including nasopharynx World Health Organization (WHO) type I-III histologies; patients can have simultaneous loco-regional disease; central biopsy review at Memorial Sloan-Kettering Cancer Center (MSKCC) is not requiredXx_NEWLINE_xXConfirmed diagnosis of AML, including treatment-related secondary AML (except prior MDS) according to World Health Organization (WHO) 2008 classification at treating institutionXx_NEWLINE_xXFrozen section diagnosis of World Health Organization (WHO) grade IV glioma, confirmed with permanent section and immunopositive for IGF-1RXx_NEWLINE_xXA diagnosis of acute myeloid leukemia (AML) based on World Health Organization (WHO) classification (>= 20% myeloblasts in peripheral blood or bone marrow)Xx_NEWLINE_xXPatients must have a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL) of non-GCB subtype, established according to the World Health Organization (WHO) criteria that has been tested for the MyD88 L265P mutation.Xx_NEWLINE_xXEastern Cooperative Oncology Group (World Health Organization) performance status of 0 or 1Xx_NEWLINE_xXNewly-diagnosed AML by World Health Organization (WHO) criteria (>= 20% myeloid blasts by morphology in either blood or marrow)Xx_NEWLINE_xXHistologically or cytologically confirmed AML, other than acute promyelocytic leukemia, as defined by the 2008 World Health Organization (WHO) criteria that is relapsed or refractory to standard chemotherapy; Note: newly-diagnosed AML patients who are 60 years or older and are not candidates for or have refused standard chemotherapy are also eligible for this trialXx_NEWLINE_xXHistologically confirmed GBM or World Health Organization (WHO) Grade IV variants (gliosarcoma, glioblastoma with oligodendroglial features, or giant cell glioblastoma).Xx_NEWLINE_xXSubject is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:Xx_NEWLINE_xXHistologically confirmed glioblastoma multiforme (GBM) (World Health Organization [WHO] grade IV); rare GBM variants (e.g. gliosarcoma, giant cell GBM, small cell GBM, GBM with oligodendroglioma features, GBM with primitive neuroectodermal tumor [PNET] features) are allowed; patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of GBM is madeXx_NEWLINE_xXBiopsy-proven diagnosis of cHL (regardless of Hodgkin/Reed-Stemberg [HRS] cell cluster of differentiation [CD]20 expression) per the World Health Organization classification criteria; lymphocyte predominant histology is excludedXx_NEWLINE_xXConfirmed MDS by bone marrow biopsy according to World Health Organization (WHO) or French-American-British (FAB) criteriaXx_NEWLINE_xXDiagnosis of untreated “high-risk” MDS (>= 10% blasts) or AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO) classification; patients with biphenotypic AML are eligible; outside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution and cytogenetic/molecular information is available\r\n* Prior hydroxyurea for AML is permitted but should be discontinued prior to start of CPX-351 treatment\r\n* Azacitidine, decitabine, lenalidomide, and growth factors are permitted for low-risk MDS (< 10% blasts); all treatments for MDS should be discontinued prior to start of CPX-351 treatmentXx_NEWLINE_xXWorld Health Organization (WHO)-confirmed AML, other than acute promyelocytic leukemia (APL)Xx_NEWLINE_xXDocumented diagnosis of myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML), White blood cells (WBC) ? 13,000 /mm3, World Health Organization (WHO)) that meets International Prognostic Scoring System (IPSS) criteria for low or intermediate-1 risk diseaseXx_NEWLINE_xXPrior diagnosis of “high-risk” myelodysplastic syndrome (MDS) (>= 10% blasts) or AML other than acute promyelocytic leukemia (APL) with t(15;17) (q22;q12) or variants according to the 2008 World Health Organization (WHO) classification; patients with biphenotypic AML are eligibleXx_NEWLINE_xXThe patient has a diagnosis of AML according to World Health Organization (WHO) criteria.Xx_NEWLINE_xXHistologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization [WHO] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past 12 monthsXx_NEWLINE_xXHave histologically or cytologically confirmed recurrent Grade 2 or 3 LGG (oligodendroglioma or astrocytoma according to World Health Organization 2016 classification).Xx_NEWLINE_xXDiagnosis of histopathologically confirmed B-cell NHL (as per the World Health Organization [WHO] 2016 classification) including WM/LPL.Xx_NEWLINE_xXDocumentation that the participant has met the revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia vera (PV)Xx_NEWLINE_xXPatients must have a histologically or cytologically confirmed lymphoid malignancy (like Hodgkin lymphoma or one of the mature B- or T-cell non-Hodgkin lymphomas as classified by World Health Organization [WHO]) for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of a recurrent/progressive World Health Organization (WHO) grade IV malignant gliomas (glioblastoma multiforme and gliosarcoma)Xx_NEWLINE_xX3. A pathologically confirmed diagnosis of AML or CMML-2 by World Health Organization (WHO) classification that is relapsed or refractory or for which no current therapies are anticipated to result in a durable remission, or MDS by WHO classification are RAEB-1 or RAEB-2 and that have failed at least three cycles of hypomethylating therapy, or primary (PMF), post-polycythemia vera (PPMF) or post-essential thrombocythemia (PTMF) MF by WHO classification, are high-risk category by the Dynamic International Prognostic Scoring System (DIPSS Plus), have ?1% circulating blasts, and have failed treatment with ruxolitinibXx_NEWLINE_xXIndolent NHL subtypes defined according to World Health Organization guidelines:Xx_NEWLINE_xXPre-study World Health Organization (WHO) performance status of 0, 1, or 2Xx_NEWLINE_xXThe patient has cytologically proven AML as defined by the World Health Organization (WHO) classification. The pretreatment AML karyotype should be documented.Xx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of primary myelofibrosis (PMF), post-polycythemia vera (post-PV) myelofibrosis (MF), or post-essential thrombocythemia (post-ET) MF using World Health Organization CriteriaXx_NEWLINE_xXPatients must have had histologic verification of AML at original diagnosis; AML is defined according to World Health Organization (WHO) classification with >= 5% blasts in the bone marrow (M2/M3 bone marrow), with or without extramedullary diseaseXx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of non-Hodgkin lymphoma (NHL); the World Health Organization (WHO) classification will be used to sub-classify the NHL; original pathology reports will be used to confirm eligibility; review of biopsy tissue slides will be attempted, but not necessary for eligibilityXx_NEWLINE_xXHistologically proven diagnosis of supratentorial, World Health Organization (WHO) grade II or III astrocytoma, oligodendroglioma or oligoastrocytoma, with IDH mutation confirmed by central reviewXx_NEWLINE_xXPatient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumorXx_NEWLINE_xXPatients must have histologically confirmed World Health Organization (WHO) grade 2 or 3 gliomasXx_NEWLINE_xXMust have histologically confirmed DLBCL, including de novo disease or transformed disease from indolent NHL. a. High-grade B-cell lymphoma (BCL) with MYC and BCL-2 and/or BCL-6 translocations (double-hit DLBCL under DLBCL, not otherwise specified [NOS], based on the 2008 World Health Organization [WHO] classification criteria) is not eligible for this study.Xx_NEWLINE_xXDiagnosis of B cell non-Hodgkin lymphoma confirmed by World Health Organization (WHO) criteriaXx_NEWLINE_xXPatients must have histologically confirmed high grade glioma by pathology (World Health Organization [WHO] grade III and IV)Xx_NEWLINE_xXBCS treated at Kaiser, an health maintenance organization (HMO) provider, will be excluded since their SCP implementation project is underwayXx_NEWLINE_xXPatients with newly diagnosed World Health Organization (WHO) grade III or IV astrocytoma who will undergo concomitant radiation and temozolomide followed by adjuvant temozolomideXx_NEWLINE_xXReceiving health care primarily through an health maintenance organization (HMO)Xx_NEWLINE_xXAttained menopause as defined by World Health Organization CriteriaXx_NEWLINE_xXNewly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening);Xx_NEWLINE_xXPathologically confirmed diagnosis of myelodysplastic syndrome (including secondary MDS, refractory anemia with excess blasts in transformation [RAEB-T], and chronic myelomonocytic leukemia [CMML, if white blood cells count is < 13,000/mm^3]) as defined by World Health Organization or French-American-British classificationsXx_NEWLINE_xXPatients must have a World Health Organization performance status of =< 2Xx_NEWLINE_xXAim 5: Director/leader or program manager/coordinator of organization or organization representative who has been nominated to be interviewed by the organization’s director/leader or manager/coordinatorXx_NEWLINE_xXScore of >= 8 on the World Health Organization (WHO) Alcohol Use Disorders Identification Test (AUDIT, sensitivity of 0.8)Xx_NEWLINE_xXTumor pathology: suspected or confirmed newly diagnosed or recurrent malignant gliomas World Health Organization (WHO) grade IVXx_NEWLINE_xXPathologically confirmed, well differentiated functioning or non-functioning metastatic GEP-NET (Grade I and II as per World Health Organisation classification 2010)Xx_NEWLINE_xXDiagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis per World Health Organization 2008 criteriaXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed newly-diagnosed glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV/IV) and be planning to undergo standard chemoradiation treatmentXx_NEWLINE_xXHas experienced clinical benefit from an EGFR TKI, followed by systemic progression of disease [Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1] or World Health Organization (WHO)] while on continuous treatment with an EGFR TKIXx_NEWLINE_xXHistologically confirmed diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) per 2016 World Health Organization (WHO) criteriaXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of classical Hodgkin lymphoma including nodular sclerosis, mixed cellularity, lymphocytic-rich, and lymphocyte depleted subtypes by the 4th edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues published in 2008Xx_NEWLINE_xXDocumented diagnosis of myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML) by World Health Organization (WHO) criteria or AML with 20-30% myeloblasts (refractory anemia with excess blasts in transformation [RAEB-T] by French-American-British [FAB)] criteria)Xx_NEWLINE_xXPathologic evidence (either diagnostic pathology slides or pathology report) of a diagnosis of World Health Organization (WHO) grade II or III glioma prior to treatment with temozolomide or PCV chemotherapyXx_NEWLINE_xXPatients must have been diagnosed with high-grade glioma:\r\n* World Health Organization (WHO) grade III: anaplastic astrocytoma, oligodendroglioma, ependymoma, or oligoastrocytoma; OR\r\n* WHO grade IV: glioblastoma multiforme; or neuroepithelial tumors of uncertain origin (polar spongioblastoma, astroblastoma, or gliomatosis cerebri)Xx_NEWLINE_xXGood physical health (no unstable medical or mental health condition)Xx_NEWLINE_xXUnstable healthXx_NEWLINE_xXHistologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO 2000] classification).Xx_NEWLINE_xXDiagnosis of MDS or AML other than APL with t(15;17)(q22;q12), (promyelocytic leukemia[PML]/retinoic acid receptor [RAR]), or variants according to the 2008 World Health Organization (WHO) classificationXx_NEWLINE_xXRelapsed or refractory AML (Acute Myeloid Leukemia) (Parts A and B) or relapsed or refractory high-risk MDS (Myelodysplastic Syndrome) (Part B only) as defined by World Health Organization criteria who are not suitable for other established therapies.Xx_NEWLINE_xX